Pancreatic cancer is the third leading cause of cancer-related death in the United States. It has a five-year survival rate of just nine percent. Lack of effective treatments and early detection methods contribute to this grim prognosis. Personalized approaches to match a patients genomic information to therapies have led to improvements in treatment of other cancer types. None of the genetic mutations commonly seen in pancreatic cancer, however, have druggable targets. Read more . . .
Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, and pancreatic cancer specialists at the University of Chicago Medicine, announce a new collaboration aimed at accelerating the pace of discovery and, over time, improving treatment of pancreatic cancer.